Benitec Biopharma (BNTC) Assets Average (2020 - 2025)

Benitec Biopharma (BNTC) has 6 years of Assets Average data on file, last reported at $143.4 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average rose 93.93% year-over-year to $143.4 million; the trailing twelve-month figure through Dec 2025 stood at $143.4 million (up 93.93% YoY), and the FY2025 full-year result was $75.9 million, up 167.85% from the prior year.
• Assets Average improved to $143.4 million in Q4 2025, from $97.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $143.4 million in Q4 2025 to a low of $6.3 million in Q2 2023.
• A 5-year average of $33.2 million and a median of $16.7 million in 2021 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 53.93% in 2022 and soared 429.87% in 2024, its largest moves.
• Tracing BNTC's Assets Average over 5 years: stood at $15.9 million in 2021, then retreated by 5.75% to $15.0 million in 2022, then soared by 61.25% to $24.2 million in 2023, then surged by 205.42% to $73.9 million in 2024, then surged by 93.93% to $143.4 million in 2025.
• Business Quant data shows BNTC's Assets Average at $143.4 million in Q4 2025, $97.8 million in Q3 2025, and $73.9 million in Q4 2024.